Servier

Diversified pharma

Privately held: no public share price · France

Assets

(6 total)
6Total Assets
2Approved
2Phase 3 / Filed
2Phase 1–2 / Early
6Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
Ivabradine(Corlanor)
Approved
If (funny) channelSmall molecule
Heart Failure
Ivosidenib(Tibsovo)
Approved
Mutant IDH1Small molecule
Acute Myeloid Leukemia
Phase 3
Protein kinase C (PKC) (inhibitor)Small molecule
Uveal Melanoma
Teneligliptin(Tenelia)
Phase 3
DPP-4Small molecule
Type 2 Diabetes
Phase 1/2
KCNT1 mRNARNA / oligonucleotide
Epilepsy
Phase 1/2
RAFSmall molecule
Non-Small Cell Lung CancerAcute Myeloid Leukemia

Upcoming events

(13 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (8)
January 2027 (2)
DarovasertibPhase 2/3Metastatic Uveal Melanoma
Est. primary completion 2027-01-15 · NCT05987332 · CT.gov ↗
What to watch
DarovasertibPhase 1/2Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
Est. primary completion 2027-01-29 · NCT03947385 · CT.gov ↗
What to watch
April 2027 (1)
DarovasertibPhase 2Uveal Melanoma
Est. primary completion 2027-04-30 · NCT05907954 · CT.gov ↗
What to watch
September 2027 (1)
Ivosidenib · TibsovoPhase 1/2Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Est. primary completion 2027-09-13 · NCT06501625 · CT.gov ↗
What to watch
October 2027 (1)
Ivosidenib · TibsovoPhase 3Acute Myeloid Leukemia (AML)
Est. primary completion 2027-10-15 · NCT05907057 · CT.gov ↗
What to watch
November 2027 (2)
S241656Phase 1/2Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Acute Myeloid Leukemia
Est. primary completion 2027-11-01 · NCT07719348 · CT.gov ↗
What to watch
Ivosidenib · TibsovoPhase 3Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
Est. primary completion 2027-11-01 · NCT06465953 · CT.gov ↗
What to watch
December 2027 (1)
Ivosidenib · TibsovoPhase 3Cholangiocarcinoma
Est. primary completion 2027-12-01 · NCT05876754 · CT.gov ↗
What to watch
2028 (3)
February 2028 (1)
Ivosidenib · TibsovoPhase 3Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation …
Est. primary completion 2028-02-01 · NCT06127407 · CT.gov ↗
What to watch
April 2028 (1)
S230815Phase 1/2Epileptic Encephalopathy
Est. primary completion 2028-04-15 · NCT07227857 · CT.gov ↗
What to watch
June 2028 (1)
S241656Phase 1/2Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation …
Est. primary completion 2028-06 · NCT05786924 · CT.gov ↗
What to watch
2030 (1)
October 2030 (1)
DarovasertibPhase 3Uveal Melanoma
Est. primary completion 2030-10 · NCT07015190 · CT.gov ↗
What to watch
2034 (1)
March 2034 (1)
DarovasertibPhase 3Uveal Melanoma
Est. primary completion 2034-03 · NCT07804186 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 June 2026Topline resultDarovasertibOptimUM-02 complete primary analysis data presented at ASCO
13 April 2026Topline resultDarovasertibOptimUM-02 Phase 2/3 (NCT05987332) met its primary endpoint: PFS by BICR
IDEAYA Biosciences · Source ↗

Financial reports

No financial reports recorded.